TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04617392

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic sleeve gastrectomy
Description: Sleeve gastrectomy involves removing a part of the stomach, limiting the amount of food the patient can eat.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strength endurance training
Description: Patients included in the active cohort arm with physical activity will undergo three months of strength endurance training under the supervision of a professional physiotherapist
Study: NCT05341947

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated T cells
Description: Activated T cells (ATC) administered intravenously at one timepoint
Study: NCT05024474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training (IMT)
Description: Inspiratory muscle training (IMT) at 20-50 % of maximal inspiratory pressure (MIP), 2 x 30 repetitions, twice a day for 8 weeks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physical exercise
Description: A physical exercise program at least two times a week for 8 weeks. Including strength, aerobic and mobility exercises.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical exercise
Description: A physical exercise program at least two times a week for 8 weeks. Including strength, aerobic and mobility exercises.
Study: NCT05208372

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC test
Description: Circulating tumor cells test of ascites and blood for patients with gastric cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: CTC test
Description: Circulating tumor cells test of ascites and blood for patients with gastric cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA test
Description: Circulating tumor DNA test of ascites and blood for patients with gastric cancer.

Intervention type: DIAGNOSTIC_TEST
Intervention: ctDNA test
Description: Circulating tumor DNA test of ascites and blood for patients with gastric cancer.
Study: NCT06478992

Intervention type: PROCEDURE
Group type: OTHER
Intervention: A:hysteroscopic suture fixation of Mirena
Description: A(the thickness of the thickest uterine myometrium ≥30mm ):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
Study: NCT05878574

Intervention type: DRUG
Intervention: Low molecular weight heparin
Description: Continuous use of LMWH for more than 3 months during pregnancy preparation and through pregnancy
Study: NCT06478992

Intervention type: PROCEDURE
Group type: OTHER
Intervention: A: simple Mirena placement under hysteroscopy
Description: A(the thickness of the thickest uterine myometrium ≥30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: B: hysteroscopic suture fixation of Mirena
Description: B(the thickness of the thickest uterine myometrium\<30mm):The Mirena is fixed to the uterine wall under hysteroscopy, and the endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.

Intervention type: PROCEDURE
Group type: OTHER
Intervention: B：simple Mirena placement under hysteroscopy
Description: B(the thickness of the thickest uterine myometrium\<30mm):Mirena is routinely placed in the uterine cavity under hysteroscopy, and endometrial tissue was routinely aspirated and scraped during the operation and sent for pathological examination.
Study: NCT05425199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Habituation exercises + vestibular treatment
Description: Exercises will include Intensity: 10 repetitions of each set Frequency= 3 sessions per week for 6 weeks.~Time= 30 minutes

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proprioceptive training + vestibular therapy
Description: Exercise protocol will include Time= total session of 30 minutes . Each exercise will be hold for 30 seconds . Frequency= 3 session per week for 6 weeks Intensity= 10 repetitions and 3 sets

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: conventional vestibular treatment
Description: Epley's Manuever. Frequency= It will be performed once in a week . Time= 10-15 minutes per session
Study: NCT06394271

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EVAR
Description: Catheter based insertion of aortic endograft via iliac or femoral arteries
Study: NCT05123612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fiber
Description: Additional 20 grams of fiber/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fiber
Description: Additional 20 grams of fiber/day.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented Foods
Description: 6 servings of fermented foods/day
Study: NCT04516408

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Recombinant zoster vaccine
Description: Recombinant zoster vaccine (RZV) is indicated for prevention of herpes zoster in adults aged ≥ 50 years old. RZV contains a varicella zoster virus glycoprotein E antigen and the AS01B adjuvant system.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterilized water
Study: NCT05532579

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invasive Physiotherapy Group
Description: The study participants corresponding to the intervention group will receive the treatment proposed by their medical doctor. In addition, and as the main part of the intervention, they will receive an invasive physiotherapy protocol consisting of 3 sessions of ultrasound-guided percutaneous neuromodulation, with a time margin of one week between the first and second session and two weeks between the second and third session. The session will last approximately 15 minutes. Each treatment session will consist of the application of a symmetric biphasic current of 3Hz frequency, 250µsec pulse width, 10 impacts of 10 seconds duration with 10 seconds of rest between them. This application will be performed with acupuncture needles placed in an echoguided manner in the proximity of the dorsal root of the last 3 lumbar levels and in the proximity of the sciatic nerve at its exit from the piriformis muscle.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sham Group
Description: Study participants corresponding to the sham group will receive the treatment proposed by their medical doctor. In addition, they will receive the application of the simulated transcutaneous electrical stimulation technique, placing the patches on the same points where the needles are located, remaining in prone position for the necessary time after the technique is performed until 15 minutes have elapsed. This technique has been studied as a placebo technique for neuromodulation interventions.
Study: NCT05123612

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fermented Foods
Description: 6 servings of fermented foods/day
Study: NCT05804721

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apipe (Aripiprazole10 mg)
Description: Test drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Abilify (Aripiprazole10 mg)
Description: Reference drug
Study: NCT04607343

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rehabilitation device based on electrical stimulation
Description: Experimental tests with transcutaneous electrical stimulation at different intensities and at the points of the submandibular region previously explored will be conducted first of all on the five healthy volunteer subjects. During these tests, the neuromuscular thresholds of the upper airway, the most effective points of electrostimulation and the tolerance of intervention will be determined. The determination of the functional threshold will be made by clinical evaluation of the subject during stimulation.
Study: NCT04906694

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: COVI-DROPS
Description: COVI-DROPS is a fully human monoclonal antibody which is a neutralizing antibody to SARS-CoV-2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Diluent solution
Study: NCT05087108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OsciPulse system
Description: The OsciPulse system is an intermittent pneumatic limb compression system. The OsciPulse sleeves that are applied to the top portion of the user's calves and are periodically inflated with rapid bursts of compressed air to create frequent pulses of venous return.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Reference Therapy 1
Description: The Venaflow Elite is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Venaflow system sleeves cover the entire calf region of the user and contain two bladders that are inflated sequentially to induce venous return.
Study: NCT06325111

Intervention type: OTHER
Intervention: Determinants of T1D glycaemic control
Description: DNA genotyping, microbiome, DNA methylation and microRNAs analysis

Intervention type: OTHER
Intervention: Determinants of T1D glycaemic control
Description: DNA genotyping, microbiome, DNA methylation and microRNAs analysis
Study: NCT05530577

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Semaglutide (subcutaneous)

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Sham/placebo
Description: Sham subcutaneous injection
Study: NCT06555848

Intervention type: DEVICE
Intervention: CERAMENT G
Description: CERAMENT G is intended for use as a bone void filler as an adjunct to systemic antibiotic therapy and surgical debridement (standard treatment approach to a bone infection) as part of the surgical treatment of osteomyelitis. By eluting gentamicin, CERAMENT G can reduce the recurrence of chronic osteomyelitis from gentamicin-sensitive microorganisms in order to protect bone healing.
Study: NCT03816228

Intervention type: DRUG
Intervention: F 18 T807 Flortaucipir
Description: Participants will receive a single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807. For those who cannot tolerate the full exam, participants will receive single intravenous bolus injection of approximately 6.5-10mCi (240-370MBq) of F 18 T807.
Study: NCT04745663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-Iodine 0.3%
Description: Low concentration iodine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Povidone-Iodine 5%
Description: Standard concentration iodine
Study: NCT05263609

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib
Description: If pembrolizumab infusions alone do not reduce the patient's tumor size by at least 60%,the patient will be placed in Arm B and start axitinib in addition to continuing pembrolizumab therapy (see Arm B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: If pembrolizumab results in a reduction in tumor size that is greater than 60%, the patient will be placed in Arm A and continue pembrolizumab infusions (see Arm A).
Study: NCT04157426

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Percutaneous electrolysis
Description: Ultrasound-guided percutaneous electrolysis in the active myofascial trigger point of the levator scapulae muscle
Study: NCT06293664

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: α-MSH infusion
Description: Pharmaceutical grade α-MSH is custom synthesized to GMP standards by Auspep (Australia www.auspep.com.au), a good manufacturing practice (GMP) accredited manufacturer of peptides, approved by the Therapeutic Goods Administration (TGA), European Medicines Agency (EMA) and U.S. Food and Drug Administration (FDA).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo solutions
Description: Pharmaceutical GMP-grade sterile 0.5% human albumin dissolved in saline.
Study: NCT04157426

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Ultrasound-guided dry needling the active myofascial trigger point of the levator scapulae muscle
Study: NCT03769688

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cervicovaginal secretions
Description: Same as arm descriptions

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole gel
Description: 5 day course of vaginal MetroGel will be used prior to VMT intervention.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Metronidazole gel
Description: 5 day course of vaginal MetroGel will be used prior to VMT intervention.

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Screening tests
Description: Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.

Intervention type: DIAGNOSTIC_TEST
Group type: PLACEBO_COMPARATOR
Intervention: Screening tests
Description: Diagnostic testing for a broad range of infectious pathogens in blood, vaginal swab, and urine samples, for general immunocompetence, and for potential pregnancy.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Activities restriction
Description: Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.
Study: NCT06479187

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 18F-rhPSMA-7.3
Description: radiopharmaceutical targeting PSMA and used to image prostate cancer with PET scan.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PET/CT
Description: Diagnostic imaging test
Study: NCT03769688

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Activities restriction
Description: Required abstinence from sexual intercourse, usage of insertive vaginal feminine products (i.e. Tampons, menstrual cups, sex toys), other vaginal products (cleansing products, spermicides, lubricants, hygiene powders and sprays), and avoidance of behaviors including taking baths, going swimming, sitting in hot tub, or wearing thong underwear. Sanitary napkins are acceptable.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Sterile Saline placebo
Description: This will be administered as a placebo in place of cervicovaginal secretions
Study: NCT05087108

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Refence Therapy 2
Description: The Kendall SCD device is a sequential compression device that uses compressed air to inflate sleeves worn on the calf of the user to stimulate venous return. The Kendall SCD sleeves cover the entire calf region of the user and contain three bladders that are inflated sequentially to induce venous return.
Study: NCT06131788

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational hand hygiene intervention
Description: The intervention combines training in hand-washing with the supply of a single-use alcohol-based hand rub, called MONO-RUB
Study: NCT05090826

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Model ZFR00V
Description: Investigational intraocular lens replaces the natural lens removed during cataract surgery in one or both eyes.
Study: NCT06249256

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fast CAR T cells
Description: Subjects will undergo leukapheresis to isolate peripheral blood mononuclear cells (PBMCs) for the production of Fast CAR T cells. During Fast CAR T cells production, subjects will receive cyclophosphamide and fludarabine for the purpose of lymphocytes depletion. After lymphodepletion, subjects will receive one dose treatment with Fast CAR T cells by intravenous (IV) injection.
Study: NCT06020027

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Water is K'é
Description: Four-month multi-level, family-based intervention that is grounded in Navajo culture and promotes individual knowledge, motivation and skills; social norms; and environmental changes (access to drinking water). At minimum, the enrolled child and primary caregiver will attend monthly sessions, with an open invitation to other family members. Families will also receive social media posts and develop a family access plan by selecting strategies (if needed) to boost their confidence in their water sources at home. ECE sites will also develop a tailored access plan, selecting strategies to increase confidence in water offered at the ECE site, and implement their access plan with study team support.
Study: NCT06317077

Intervention type: OTHER
Group type: OTHER
Intervention: PAP therapy setting
Description: Subtherapeutic phases during titration to provoke breathing events after reaching the pressure level with which the breathing events are sufficiently treated

Intervention type: OTHER
Group type: OTHER
Intervention: exclusive use of Löwenstein Medical full face masks
Description: Use of a Löwenstein Medical full face mask as a requirement for participation in the clinical investigation
Study: NCT06391957

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Spirulina supplement
Description: Participants consume a 3g spirulina supplement 3 times daily for 5 consecutive days.

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Eccentric exercise
Description: On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Description: On the morning of Day 3 (where Day 1 is when participants start taking supplements), participants perform a single bout of eccentric exercise. The exercise protocol is performed on a single leg and involves 300 (10 sets of 30 repetitions separated by 120 seconds) voluntary maximal, isokinetic, eccentric contractions of the knee extensor. Exercise is performed using a Biodex System 3 isokinetic dynamometer (Biodex Medical Systems, Shirley, NY, USA), and contractions are performed at 60◦/s over an 80◦ range of motion.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo supplement
Description: Participants consume a macronutrient matched placebo supplement 3 times daily for 5 consecutive days.
Study: NCT05228106

Intervention type: DIAGNOSTIC_TEST
Intervention: [68Ga]-PSMA-617
Description: The intervention consists of an intravenous injection of the radiopharmaceutical \[68Ga\]-PSMA-617 and a physiological saline flush, followed 60-90 minutes later by a PET/CT image acquisition.
Study: NCT05138783

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Verofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear

Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study: NCT05756504

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac
Description: Injection ketorolac 30 mg IV x TDS will be given to each patient in each group.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol
Description: Injection Tramadol 25-50 mg IV x TDs wil be given to each patient in this group. Maximum dose will be 400 mg/ day
Study: NCT05138783

Intervention type: DEVICE
Group type: OTHER
Intervention: Nesofilcon A contact lenses
Description: Spherical soft contact lenses for daily disposable wear
Study: NCT06468293

Intervention type: OTHER
Group type: OTHER
Intervention: Psychological support
Description: Psychological support intervention
Study: NCT06437418

Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasonography.
Description: Evaluate the gallbladder ejection fraction (EF)

Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasonography.
Description: Evaluate the gallbladder ejection fraction (EF)

Intervention type: DIAGNOSTIC_TEST
Intervention: abdominal ultrasonography.
Description: Evaluate the gallbladder ejection fraction (EF)
Study: NCT05291455

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lacosamide
Description: lacosamide will be given

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital
Description: phenobarbital will be given
Study: NCT04628104

Intervention type: RADIATION
Intervention: cardiac magnetic resonance
Description: o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation

Intervention type: RADIATION
Intervention: cardiac magnetic resonance
Description: o CMR protocol:~* Cine imaging to assess regional \& global ventricular function according to the AHA 16-segment model.~* T2-weighted imaging to detect extent \& distribution of myocardial edema.~* Early Gd enhancement imaging to detect extent \& distribution of myocardial hyperemia.~* Late Gd enhancement imaging to detect extent \& distribution of myocardial necrosis.~* Single-short sequences \& other acceleration techniques will be used as appropriate in patients with poor ability to hold their breath.~* Post-processing analysis will be done on a dedicated workstation
Study: NCT05961098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: RBD1016 with NAs background treatment will be explored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: RBD1016 with NAs background treatment will be explored.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RBD1016
Description: RBD1016 with NAs background treatment will be explored.